ReviewJournal of clinical pharmacy and therapeutics2022
Pharmacokinetics, safety and efficacy of intra-articular non-steroidal anti-inflammatory drug injections for the treatment of osteoarthritis: A narrative review.
Review in Journal of clinical pharmacy and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Analgesic drug efficacy in mouse postoperative pain: a systematic review and meta-analysis.Lab animal · 2026Pooled it
- Do successive intra-articular injections of tenoxicam or meloxicam affect the treatment outcomes of temporomandibular joint anterior disc displacement with reduction? (a randomized controlled trial).Oral and maxillofacial surgery · 2026Trial
- Non-Biologic Injections in Sports Medicine.Current reviews in musculoskeletal medicine · 2026Review
- Celecoxib-loaded injectable composite microspheres for anti-inflammatory therapy in osteoarthritis.Drug delivery and translational research · 2026Article
- The Application of Novel Drug Delivery Systems in the Treatment of Osteoarthritis.Pharmaceutics · 2025Review
- Multiscale characterization of ultrasmall fluorescent core-shell silica nanoparticles in cartilage and synovial joints reveals rapid cartilage penetration and sustained joint residence.Acta biomaterialia · 2025Article
- Optimal frequency of platelet-rich plasma injections for managing osteoarthritis: A longitudinal study.Regenerative therapy · 2025Article
- A mechanically resilient soft hydrogel improves drug delivery for treating post-traumatic osteoarthritis in physically active joints.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Liposome-Based Interventions in Knee Osteoarthritis.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Therapeutic Controlled Release Strategies for Human Osteoarthritis.Advanced healthcare materials · 2025Review
- Heat-KilledNutrients · 2024Article
- Obesity-induced fibrosis in osteoarthritis: Pathogenesis, consequences and novel therapeutic opportunities.Osteoarthritis and cartilage open · 2024Review
- Short-Term Celecoxib Promotes Bone Formation without Compromising Cefazolin Efficacy in an Early Orthopaedic Device-Related Infection: Evidence from a Rat Model.Antibiotics (Basel, Switzerland) · 2024Article
- Spinosin ameliorates osteoarthritis through enhancing the Nrf2/HO-1 signaling pathway.European journal of histochemistry : EJH · 2024Article
- Pain Management Strategies in Osteoarthritis.Biomedicines · 2024Review
- Nonsteroidal Anti-Inflammatory Drug Injections versus Steroid Injections in the Management of Upper and Lower Extremity Orthopedic Conditions: A Systematic Review with Meta-Analysis.Journal of clinical medicine · 2024Review
- Improved Cartilage Protection with Low Molecular Weight Hyaluronic Acid Hydrogel.Bioengineering (Basel, Switzerland) · 2023Article
- Mesenchymal stem/stromal cells-derived extracellular vesicles as a potentially more beneficial therapeutic strategy than MSC-based treatment in a mild metabolic osteoarthritis model.Stem cell research & therapy · 2023Article
- Pharmacokinetics, safety and efficacy of intra-articular non-steroidal anti-inflammatory drug injections for the treatment of osteoarthritis: A narrative review.Journal of clinical pharmacy and therapeutics · 2022Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
WHAT IS KNOWN AND
objectiveOsteoarthritis (OA) is a common cause of joint disease and activity limitation in adults. Common therapies to treat OA-related pain are oral and topical non-steroidal anti-inflammatory drugs (NSAIDs) and intra-articular (IA) corticosteroids. However, prolonged courses of oral NSAIDs are associated with systemic adverse effects and repeat IA corticosteroid injections may cause cartilage degeneration. IA NSAIDs may be an alternative therapy possibly minimizing systemic side effects while maintaining efficacy. Therefore, we sought to summarize the pharmacokinetics, safety and efficacy of IA NSAIDs to help providers make a more informed decision on the use of IA NSAIDs.
methodsWe searched the National Library of Medicine Database with terms "intraarticular and nsaid", yielding 1032 results. Only traditional formulations of NSAIDs were considered for inclusion. Animal studies were included if animals were healthy or if the method of arthritis induction was a reasonable model of osteoarthritis. Human studies were included if humans were healthy or if the primary disease studied was osteoarthritis of a large joint. Of 1032 results, 31 research articles met the inclusion criteria and were summarized in this review. RESULTS AND DISCUSSION: We found that single doses of IA NSAIDs provided far less total systemic and synovial exposure compared to a one week course of oral NSAIDs, but maximum concentrations to the synovium with IA administration were much higher. IA NSAIDs had an excellent safety profile in small animals, large animals and humans, although these injections were associated with non-specific cartilage inflammation in healthy animals. In animal models, IA NSAIDs had similar efficacy to PO NSAIDs in treating OA-related pain. In humans, IA NSAIDs had similar efficacy to PO NSAIDS and IA corticosteroids in treating OA-related pain; however, many trials did not have a placebo control and outcome measures were heterogeneous. WHAT IS NEW AND
conclusionOverall, single doses of IA NSAIDs appear safe and efficacious across animals and humans. The optimal use of IA NSAIDs is still to be determined and further research is needed. However IA NSAIDs may be an additional beneficial therapy to treat OA-related pain. Potential uses may be to augment IA corticosteroids injections, to interrupt multiple IA corticosteroid injections or as an alternative in patients that are high risk for corticosteroid-related adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.